RG 7112

Drug Profile

RG 7112

Alternative Names: R 1772; R-7112; RG-7112; RO-5045337

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Haematological malignancies; Liposarcoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Nov 2013 Roche completes a phase I trial in Acute myeloid leukaemia (combination therapy) in USA, Canada, France, Italy and the UK (NCT01635296)
  • 25 Jul 2013 Discontinued - Phase-I for Acute myeloid leukaemia (combination therapy) in USA, Canada, France, Italy and United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top